J
John W. Baddley
Researcher at University of Alabama at Birmingham
Publications - 170
Citations - 14088
John W. Baddley is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Transplantation & Histoplasmosis. The author has an hindex of 56, co-authored 158 publications receiving 11675 citations. Previous affiliations of John W. Baddley include University Medical Center New Orleans & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia.
TL;DR: Outcomes, including mortality and resolution of infection, among 20 (17%) patients with fluconazole-resistant and fluconzole-susceptible dose-dependent isolates were relatively poor compared to those among patients withfluconazoles-suspicious isolates, but probably reflect severity of illness.
Journal ArticleDOI
Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya.
Rennatus Mdodo,Stephen A. Moser,Walter Jaoko,John W. Baddley,Peter G. Pappas,Mirjam-Colette Kempf,Inmaculada Aban,Susan Odera,Pauline E. Jolly +8 more
TL;DR: High susceptibilities of incident C. neoformans isolates to FLC and AMB, antifungals used for treatment of cryptococcal meningitis in Kenya are demonstrated.
Journal ArticleDOI
Opportunistic Infections in Biological Therapy, Risk and Prevention
Paul A. Bryant,John W. Baddley +1 more
TL;DR: The incidence of certain opportunistic infections has been rigorously evaluated in large observational studies, however, data are more limited for other infections (histoplasmosis, nontuberculous mycobacteria).
Journal ArticleDOI
Herpes Zoster and the Risk of Stroke in Patients With Autoimmune Diseases.
Leonard H. Calabrese,Fenglong Xie,Huifeng Yun,Kevin L. Winthrop,John W. Baddley,Cassandra Calabrese,Jeffrey R. Curtis +6 more
TL;DR: Herpes zoster is an opportunistic infection caused by varicella‐zoster virus and observed with increasing frequency in patients receiving immunosuppressive therapies and in patients with autoimmune diseases, who are at increased risk of both zoster and stroke.
Journal ArticleDOI
Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis.
TL;DR: Pneumocystis jirovecii pneumonia is an important opportunistic infection that has been increasingly reported in patients with rheumatic disease and trimethoprim–sulfamethoxazole is believed to be the most effective agent for treatment and prophylaxis, but is associated with significant adverse effects.